Holen Sie sich die Stockscreener-App
0.31
6.90%
0.02
Handel nachbörslich:
.31
Schlusskurs vom Vortag:
$0.29
Offen:
$0.281
24-Stunden-Volumen:
4.35M
Relative Volume:
1.04
Marktkapitalisierung:
$7.08M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.71M
KGV:
-0.0265
EPS:
-11.71
Netto-Cashflow:
$-18.24M
1W Leistung:
+5.80%
1M Leistung:
-7.46%
6M Leistung:
-82.87%
1J Leistung:
-87.30%
1-Tages-Spanne:
$0.2807
$0.3606
1-Wochen-Bereich:
$0.2601
$0.3606
52-Wochen-Spanne:
$0.22
$4.0899
Genprex Inc Stock (GNPX) Company Profile
Firmenname
Genprex Inc
Sektor
Branche
Telefon
512-537-7997
Adresse
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Vergleichen Sie GNPX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
0.31 | 7.08M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-01-26 | Eingeleitet | National Securities | Buy |
| 2019-04-29 | Eingeleitet | Noble Capital Markets | Outperform |
Genprex Inc Aktie (GNPX) Neueste Nachrichten
Geode Capital Management LLC Grows Position in Genprex, Inc. (NASDAQ:GNPX) - Defense World
Genprex Inc (NASDAQ: GNPX) Is The Number One Stock Currently Moving. - Stocksregister
Genprex (GNPX) Showcases Promising Results for Reqorsa Gene Ther - GuruFocus
Genprex Collaborators Report Positive Preclinical Data On The Use Of Reqorsa Gene Therapy - TradingView
Genprex Collaborators Report Positive Preclinical Data on the Us - GuruFocus
Financial Metrics Check: Genprex Inc (GNPX)’s Ratios for Trailing Twelve Months - DWinneX
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer at the 2025 AACR Annual Meeting - PR Newswire
Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - The Malaysian Reserve
Genprex Collaborators to Present Positive Preclinical Data on Di - GuruFocus
Taking the lead: Genprex Inc (GNPX) - Sete News
Understanding the Risks of Investing in Genprex Inc (GNPX) - knoxdaily.com
Genprex (GNPX) Secures Exclusive Patent License for Mesothelioma - GuruFocus
Indo-Asian News Service - Indo-Asian News Service (IANS)
Genprex secures exclusive license for mesothelioma gene therapy By Investing.com - Investing.com South Africa
Genprex secures exclusive license for mesothelioma gene therapy - Investing.com Australia
Choosing between riding the trend or protecting profits: Genprex Inc (GNPX) - uspostnews.com
Genprex Inc (NASDAQ: GNPX) Stock’s Potential for Success in the Coming Months - Marketing Sentinel
Genprex Signs Exclusive Technology License Agreement with New Yo - GuruFocus
Genprex (GNPX) Secures Exclusive License for Gene Therapy Patent - GuruFocus
Genprex Signs Agreement With New York University Langone Health - marketscreener.com
Revolutionary Gene Therapy Shows 84% Target Success in Mesothelioma Treatment: Genprex-NYU Partnership - Stock Titan
Short Interest in Genprex, Inc. (NASDAQ:GNPX) Grows By 487.6% - Defense World
Stock Market Recap: Genprex Inc (GNPX) Concludes at 0.27, a 0.57 Surge/Decline - DWinneX
GNPX’s Stock Market Puzzle: Piecing Together 2023’s Performance - investchronicle.com
Now Is The Time To Build A Position In Genprex Inc (NASDAQ:GNPX) - Marketing Sentinel
Genprex Selected to Present Trial Design of Acclaim-3 Clinical T - GuruFocus
Genprex Selected to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting - Seeking Alpha
Genprex Inc (GNPX) receives a Buy rating from National Securities - knoxdaily.com
Genprex presents promising gene therapy data for lung cancer By Investing.com - Investing.com South Africa
How Are Things Looking For Genprex Inc (NASDAQ: GNPX) For The Short Term? - Stocksregister
Genprex presents promising gene therapy data for lung cancer - Investing.com
Genprex Announces Research Collaborators' Abstract Published in Cancer Research Supplement Proceedings - GuruFocus
There is no doubt that Genprex Inc (GNPX) ticks all the boxes. - Sete News
Genprex Announces Research Collaborators' Abstract Published in - GuruFocus
Cancer Research Reveals Breakthrough: Gene Therapy Defeats Drug-Resistant Lung Cancer in Latest Study - Stock Titan
Ratio Examination: Genprex Inc (GNPX)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Genprex, Inc. (NASDAQ:GNPX) Short Interest Update - Defense World
Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer (PR Newswire) - Aktiellt
What Analysts Were Expecting After Genprex Inc (NASDAQ: GNPX) fell -1.73% - stocksregister.com
Analysts Provide Insight Into Genprex Inc’s (GNPX) Potential. - Stocksregister
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Genprex Delays Yearly Report Filing - TipRanks
Genprex Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Genprex, Inc. SEC 10-K Report - TradingView
Genprex (GNPX) Projected to Announce Earnings on Monday - Defense World
Genprex stock plunges to 52-week low of $0.27 By Investing.com - Investing.com South Africa
Genprex stock plunges to 52-week low of $0.27 - Investing.com India
Genprex reports progress in lung cancer gene therapy By Investing.com - Investing.com South Africa
Finanzdaten der Genprex Inc-Aktie (GNPX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):